Circulating endothelial cells and their progenitors in acute myeloid leukemia

Zahran,Asmaa  Mohammed; Aly,Sanaa  Shaker; Altayeb,Hanan  Ahmed; Ali,Arwa  Mohammed

doi:10.3892/ol.2016.4859

Circulating endothelial cells and their progenitors in acute myeloid leukemia

Authors:
- Asmaa Mohammed Zahran
- Sanaa Shaker Aly
- Hanan Ahmed Altayeb
- Arwa Mohammed Ali
View Affiliations

Affiliations: Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut 71111, Egypt, Department of Clinical Pathology, Faculty of Medicine, South Valley University, Qena 83523, Egypt, Department of Medical Oncology, South Egypt Cancer Institute, Assiut University, Assiut 71111, Egypt
Published online on: July 13, 2016 https://doi.org/10.3892/ol.2016.4859
Pages: 1965-1970

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the accumulation of immature myeloid progenitor cells in the bone marrow. Studies are required to investigate the prognostic and predictive value of surrogate biomarkers. Given the importance of angiogenesis in oncology in terms of pathogenesis as well as being a target for treatment, circulating endothelial cells (CECs) and endothelial progenitor cells (EPCs) are promising candidates to serve as such markers. The aim of the present study was to quantify CECs and EPCs in patients with AML at initial diagnosis and following induction chemotherapy, and to correlate these findings with the response to treatment in AML patients. The present study included 40 patients with de novo AML and 20 age‑ and gender‑matched healthy controls. CECs and EPCs were evaluated by flow cytometry at initial diagnosis and after induction chemotherapy (3+7 protocol for AML other than M3 and all‑trans‑retinoic acid plus anthracycline for M3 disease). CECs and EPCs were significantly higher in AML patients at diagnosis and after induction chemotherapy than in controls. After induction chemotherapy, CECs and EPCs were significantly decreased compared with the levels at initial diagnosis. Patients who achieved complete response (n=28) had lower initial CEC and EPC levels compared with patients who did not respond to treatment. These results suggest that CEC levels are higher in AML patients and may correlate with disease status and treatment response. Further investigations are required to better determine the predictive value and implication of these cells in AML management.

View Figures

View References

1	Fröhling S, Scholl C, Gilliland DG and Levine RL: Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol. 23:6285–6295. 2005. View Article : Google Scholar : PubMed/NCBI
2	Trujillo A, McGee C and Cogle CR: Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol. 2012:1286082012. View Article : Google Scholar : PubMed/NCBI
3	George F, Brisson C, Poncelet P, Laurent JC, Massot O, Arnoux D, Ambrosi P, Klein-Soyer C, Cazenave JP and Sampol J: Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: Demonstration of endothelial injury after angioplasty. Thromb Haemost. 67:147–153. 1992.PubMed/NCBI
4	Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, et al: Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost. 93:228–235. 2005.PubMed/NCBI
5	Bertolini F, Shaked Y, Mancuso P and Kerbel RS: The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer. 6:835–845. 2006. View Article : Google Scholar : PubMed/NCBI
6	Fadini GP, Losordo D and Dimmeler S: Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 110:624–637. 2012. View Article : Google Scholar : PubMed/NCBI
7	Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G and Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:964–967. 1997. View Article : Google Scholar : PubMed/NCBI
8	Ma J and Waxman DJ: Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 7:3670–3684. 2008. View Article : Google Scholar : PubMed/NCBI
9	Almici C, Skert C, Verardi R, Di Palma A, Bianchetti A, Neva A, Braga S, Malagola M, Turra A, Marini M and Russo D: Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation. 98:706–712. 2014. View Article : Google Scholar : PubMed/NCBI
10	Szmigielska-Kapłon A, Krawczyńska A, Czemerska M, Pluta A, Cebula-Obrzut B, Szmigielska K, Smolewski P, Robak T and Wierzbowska A: Circulating endothelial cell kinetics and their potential predictive value during mobilization procedure. J Clin Apher. 28:341–348. 2013.PubMed/NCBI
11	Ali AM, Ueno T, Tanaka S, Takada M, Ishiguro H, Abdellah AZ and Toi M: Determining circulating endothelial cells using cellsearch system during preoperative systemic chemotherapy in breast cancer patients. Eur J Cancer. 47:2265–2272. 2011. View Article : Google Scholar : PubMed/NCBI
12	Wu JY, Huang L, Zhou JF, Pei RZ, Ma JX, Zhang PS, Liu XH, Du XH, Chen D, Sha KY, et al: Expression of BCR/ABL fusion gene in circulating endothelial cells from chronic myelogenous leukemia patients and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 22:927–931. 2014.(In Chinese). PubMed/NCBI
13	Wierzbowska A, Robak T, Krawczyńska A, Wrzesień-Kuś A, Pluta A, Cebula B and Smolewski P: Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol. 75:492–497. 2005. View Article : Google Scholar : PubMed/NCBI
14	Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, et al: Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 113:1875–1891. 2009. View Article : Google Scholar : PubMed/NCBI
15	Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, et al: Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 21:4642–4649. 2003. View Article : Google Scholar : PubMed/NCBI
16	Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, et al: Validation of a standardized method for enumerating circulating endothelial cells and progenitors: Flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res. 15:267–273. 2009. View Article : Google Scholar : PubMed/NCBI
17	Chorváth B and Sedlák J: Hematopoietic cell differentiation antigens (CD system 1997). Cancer research relevance. Neoplasma. 45:273–276. 1998.PubMed/NCBI
18	Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal RG, Besmer P, Lyden D, Moore MA, et al: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 109:625–637. 2002. View Article : Google Scholar : PubMed/NCBI
19	Shain KH, Landowski TH and Dalton WS: The tumor microenvironment as a determinant of cancer cell survival: A possible mechanism for de novo drug resistance. Curr Opin Oncol. 12:557–563. 2000. View Article : Google Scholar : PubMed/NCBI
20	Damiano JS, Cress AE, Hazlehurst LA, Shtil AA and Dalton WS: Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93:1658–1667. 1999.PubMed/NCBI
21	Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, et al: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 13:2643–2650. 2007. View Article : Google Scholar : PubMed/NCBI
22	Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, et al: High-dose celecoxib and metronomic ‘low-dose’ cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res. 12:5190–5198. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U, et al: Circulating endothelial progenitor cells in multiple myeloma: Implications and significance. Blood. 105:3286–3294. 2005. View Article : Google Scholar : PubMed/NCBI
24	Brown AP, Citrin DE and Camphausen KA: Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev. 27:415–434. 2008. View Article : Google Scholar : PubMed/NCBI
25	Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 13:4474–4481. 2007. View Article : Google Scholar : PubMed/NCBI